NL-OMON21285已完成不适用
Ibopamine 2% eyedrops in the treatment of patients with ocular hypotony after vitreoretinal surgery for retinal detachment or uveitis; Results after six months of treatment.
未提供0 个研究点目标入组 21 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
Ganteris-Gerritsen E, Ugahary LC, Jansen J, Mulder PG, Cohen AF, van Meurs JC. Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma. Retina. 2012; 32(4):742-7. PMID: 21909052.
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Hypotony (0-5 mm Hg);
- •2. Stable eye pressure for at least 4 months;
排除标准
- •1. Chronical heart failure;
- •2. Hypotony caused by other factors than surgery or uveitis;
研究者
相似试验
已完成
不适用
Ibopamine 2% eye drops in the treatment of patients with ocular hypotony after vitreoretinal surgery for retinal detachment or uveitis: results after six months of treatmentISRCTN46178243Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) (The Netherlands)17
已完成
不适用
Ibopamine eyedrops in the treatment of hypotony after vitreoretinal surgery in retinal detachment or uveitis.NL-OMON2646415
已完成
不适用
Ibopamine eye drops in the treatment of hypotony after vitreoretinal surgery in retinal detachment or uveitisOcular hypotony following either vitreoretinal surgery or uveitisEye DiseasesDisorders of globeISRCTN36001452Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) (The Netherlands)15
进行中（未招募）
不适用
A Phase 2b Dose-Evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular DegeneratioMedDRA version: 12.0Level: LLTClassification code 10064930Term: Age-related macular degenerationAge-Related Macular DegenerationEUCTR2009-015106-19-DKGlaxoSmithKline Research and Development525
进行中（未招募）
1 期
A Phase 2b Dose-Evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular DegeneratioAge-Related Macular DegenerationEUCTR2009-015106-19-BEGlaxoSmithKline Research and Development525